← All trials
NCT04480463
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Apr 30, 2022
- First posted
- Jul 21, 2020
- Last posted
- Dec 9, 2020
- Enrollment
- 560
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sam Chun Dang Pharm. Co. Ltd.Lead sponsor
- Sam Chun Dang Pharm. Co. Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.